Objective: To assess the long-term effects including all-cause mortality, cardiovascular mortality, and fracture incidence, of cinacalcet on secondary hyperparathyroidism (SHPT) in patients on dialysis. Methods: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from their inception to October 2018. Randomized controlled trials (RCTs) and cohort design prospective observational studies assessing cinacalcet for the treatment of SHPT in dialysis patients were included. Data extraction was independently completed by 2 authors who determined the methodological quality of the studies and extracted data in duplicate. Study-specific risk estimates were tested by using a fixed effects model. Results: A total of 14 articles with 38,219 participants were included, of which 10 RCTs with 7,471 participants and 4 prospective observational studies with 30,748 participants fulfilled the eligibility criteria. Compared with no cinacalcet, cinacalcet administration reduced allcause mortality (relative risk [RR] 0.91, 95% CI 0.89-0.94, p < 0.001) and cardiovascular mortality (RR 0.92, 95% CI 0.89-0.95, p < 0.001), but it did not significantly reduce the incidence of fractures (RR 0.93, 95% CI 0.87-1.00, p = 0.05). Conclusions: The results of this meta-analysis indicated that the treatment of SHPT with cinacalcet may in fact reduce all-cause mortality and cardiovascular mortality among patients receiving maintenance dialysis.
Methods

Data Sources and Searches
We searched PubMed, Embase, and the Cochrane Library from their inception to October 2018, and we systematically identified clinical studies evaluating the effects of cinacalcet in dialysis patients. No language restriction was applied. The search strategy included terms for cinacalcet, SHPT, and hemodialysis. We also scanned the cited references of retrieved articles and all prior systemic reviews to identify any additional relevant studies.
Eligibility Criteria
We included studies that evaluated the effectiveness and safety of cinacalcet for the treatment of SHPT in dialysis patients. A published article was included if (1) it was an RCT or a casecontrol or cohort design prospective observational study, (2) the study evaluated the administration of cinacalcet alone or in combination with a vitamin D compound or phosphate binder versus the administration of placebo in combination with standard treatment or standard treatment alone, and (3) the end point events (all-cause or cardiovascular mortality and fracture incidence) and their corresponding hazard ratio (HR) or relative risk (RR) and its 95% CI were reported or could be calculated from data reported. If publications were duplicated or if the articles were from the same study population, the most recent publication was included. Excluded from this analysis were studies that were retrospective studies, those that included nondialysis patients, or those for which the HR or RR of the end point events could not be obtained.
Two authors independently screened the abstracts and full texts of all potentially eligible articles; disagreements between reviewers were resolved by a third reviewer. The risk of bias in RCTs was assessed using the Cochrane Collaboration's tool [14] . To assess the prospective observational study quality, a 9-star system based on the Newcastle-Ottawa Scale was used, in which a study was judged on 3 broad perspectives: the selection of the study groups, the comparability of the groups, and the ascertainment of either the exposure or the outcome of interest for case-control or prospective studies. A high-quality study was defined as a study that was awarded ≥7 stars (Table 1) . Our meta-analysis of RCTs and prospective observational studies were performed according to both Preferred Reporting Items for Systematic Reviews [15] and Meta-analysis Of Observational Studies in Epidemiology recommendations [16] .
Data synthesis was conducted and RevMan software (version 5.3; Cochrane Collaboration, Copenhagen, Denmark) was used for statistical analysis. To compute a summary RR with its 95% CI, we used the study-specific, most adjusted RR or HR (for all-cause mortality, cardiovascular mortality, and fracture incidence) and its 95% CI in all analyses. logHR or logRR and SElogHR or SElogOR needed to be entered. SElogHR = (logUCI-logLCI)/3.92. A p value < 0.05 was considered statistically significant. We examined heterogeneity in results across studies using the Cochran Q and I 2 statistics. The null hypothesis that the studies are homogeneous was rejected if the p value for heterogeneity was < 0.10 or if I 2 was > 50% [17, 18] . We employed a funnel plot to assess publication bias and a fixed effects model (the inverse variance method) to estimate study-specific risk.
Results
Characteristics and quality of the studies. A total of 38,219 potentially relevant citations were identified and screened. Thirteen articles were retrieved or detailed, of which 10 RCTs [6, 9, 10, 12, 19-24] with 7,471 participants and 3 prospective observational studies [13, 25, 26] with 30,748 participants fulfilled the eligibility criteria and were included in the metaanalysis ( Fig. 1 ; Table 2 ). All 14 trials included patients with stage 5 CKD who were under dialysis treatment.
All-cause mortality. We included 13 trials (including 38,219 participants) that either reported all-cause mortality or the all-cause mortality could be calculated from the data reported in 2 groups. Our results indicated that cinacalcet reduced all-cause mortality compared with placebo or no cinacalcet treatment in patients with SHPT caused by CKD (RR 0.91, 95% CI 0.89-0.94, p < 0.001) as determined using a fixed effects model (I 2 = 0%, p = 0.81; Fig. 2a, b) .
Cardiovascular mortality. Only 3 trials (including 32,309 participants) that either reported cardiovascular mortality or the all-cause mortality could be calculated from the data reported were included in our meta-analysis. The results showed that cinacalcet treatment may reduce cardiovascular mortality compared with no cinacalcet treatment in patients with SHPT caused by CKD (RR 0.92, 95% CI 0.89-0.95, p < 0.001) as determined using a fixed effects model (I 2 = 49%, p = 0.14; Fig. 3a, b) . Fracture incidence. Four trials (including 7,471 participants) that either reported the incidence of fractures or the incidence of fractures could be calculated from the data reported were included in our meta-analysis. The results showed that cinacalcet did not significantly reduce the incidence of fractures (RR 0.93, 95% CI 0.87-1.00, p = 0.05) as determined using a fixed effects model (I 2 = 7%, p = 0.36; Fig. 4a, b ).
Discussion
Although there were several published meta-analyses of RCTs examining the effects of cinacalcet on CKD-MBD, cardiovascular mortality, and all-cause mortality, this is the first meta-analysis that included RCTs and high-quality prospective observational studies to evaluate the long-term treatment effects of cinacalcet on cardiovascular mortality, all-cause a b Fig. 4 . a Forest plot on fracture incidence in the cinacalcet group versus the non-cinacalcet control group. b Funnel plot to assess publication bias in effect estimates in fracture incidence. mortality, and fracture incidence. To our knowledge, this meta-analysis of 10 RCTs and 3 prospective observational studies of patients receiving hemodialysis or peritoneal dialysis is the largest, with 36,283 participants, and the results are not in agreement with the results of previous meta-analyses [27, 28] . Previous meta-analyses included only RCTs. Owing to limited time and money, in most RCTs, observation indicators do not include death. Patients were observed only for several months, and there were almost no deaths. However, many meta-analyses discuss all-cause mortality and cardiovascular mortality [29] [30] [31] . We selected end-point events (all-cause or cardiovascular mortalities and fracture incidence) and their HR or RR and 95% CI as outcomes to report.
Evidence suggests that maintaining CKD-MBD-related mineral metabolic parameters within the K/DOQI target ranges is of significant clinical relevance [32] . Cinacalcet is widely used in clinical practice, and there is an obvious beneficial effect of cinacalcet on serum PTH, calcium, and phosphorus levels. However, it was not clear whether cinacalcet could reduce hospitalizations due to cardiovascular events, cardiovascular mortality, or all-cause mortality compared with standard treatment for CKD. The strength of the observational data suggests that high levels of calcium and phosphorus are associated with mortality. It is tempting to speculate that serum PTH, calcium, and phosphorus reductions may be the proximate cause of a survival benefit [33] . In addition, abnormal calcium and phosphorus levels in the blood and tissues are linked to vascular calcification, resulting in cardiovascular diseases. In addition, there was a significant negative correlation between PTH and all-cause mortality. It has been repeatedly confirmed that cinacalcet has a lowering effect on serum FGF-23, a marker of left ventricular hypertrophy and cardiovascular disease in the CKD population [34] [35] [36] . Therefore, in theory, improvement in the above indicators will help reduce cardiovascular mortality or all-cause mortality. In addition, some long-term high-quality prospective observational studies found that the prescription of cinacalcet to hemodialysis patients with SHPT who received traditional treatment (no-cinacalcet control group) was associated with significant reductions in all-cause and cardiovascular mortality. Our meta-analysis included evidence from both RCTs and observational studies on the effects of cinacalcet on all-cause and CV-related mortality, showing that cinacalcet may be associated with a decreased risk of all-cause (0.91, 95% CI 0.89-0.94) and CV-related mortality (0.92, 95% CI 0.89-0.95) among patients receiving maintenance dialysis. Because these results are observational and cannot establish a cause-and-effect relationship, they are not currently used in conventional therapy.
Bone remodeling is dependent on the dynamic balance between bone formation and bone resorption. Excessively high levels of serum PTH lead to an imbalance of these 2 processes and affect bone and mineral metabolism [37, 38] . El-Shafey et al. [19] reported that cinacalcet treatment increased the proximal femur BMD in patients with SHPT. In contrast, when SHPT was not effectively treated, there was a progressive loss of the proximal femur BMD. Cinacalcet treatment for 36 weeks not only halted bone loss but also resulted in a 2% increase in mineralized bone in the proximal femur; however, cinacalcet did not stop the bone loss in the lumbar spine. Some studies have demonstrated that cinacalcet ameliorated high bone turnover and increased femoral cortical bone mineral density and cortical bone strength [39] . These data suggest that cinacalcet may protect cortical bone in patients with SHPT. However, a positive result of reducing the incidence of fractures was not obtained from RCTs. Our meta-analysis results of improving fracture incidence are close to significant.
Previous studies including RCTs, meta-analyses, and observational studies found that the use of cinacalcet was correlated with a relatively high risk of adverse events, including hypocalcemia, nausea, vomiting, and diarrhea. Some findings did not indicate apparent benefits of cinacalcet therapy on mortality, which may preclude the use of cinacalcet as the first-line therapy in CKD patients with uncontrolled hyperparathyroidism. Research by Wang et al. [27] showed that the absolute risk of hypocalcemia, nausea, vomiting, and diarrhea increased by 10.31, 13.16, 10.57, and 2.01% respectively, compared with placebo or no treatment. It is also not clear whether cinacalcet affects all-cause mortality and cardiovascular mortality. These findings limited the prescription of cinacalcet by clinicians. However, in some prospective and retrospective studies, cinacalcet-induced hypocalcemia was of short duration and usually self-limited. Importantly, hypocalcemia-induced serious adverse events were very rare [40] . Accordingly, the revised 2017 KDIGO CKD-MBD guideline states that mild and asymptomatic hypocalcemia can be tolerated in patients on dialysis, especially when associated with cinacalcet treatment, to avoid inappropriate calcium loading in adults [41] . Cinacalcet initiation was more effective in patients with more severe iPTH levels than that in patients with less severe iPTH levels. We combined the results of observational studies and RCTs and found that the treatment of SHPT in dialysis with cinacalcet therapy may reduce all-cause mortality and cardiovascular mortality. Clinicians should seriously consider the benefits and harms of cinacalcet versus standard treatment to persistently control elevated PTH levels due to CKD-MBD in dialysis.
In conclusion, our meta-analysis results showed that treatment of SHPT in maintenance dialysis patients with cinacalcet therapy may reduce all-cause mortality and cardiovascular mortality. However, further RCTs investigating the effect of cinacalcet on long-term mortality and fracture incidence are required.
